Twist Bioscience (TWST) to Release Quarterly Earnings on Monday

Twist Bioscience (NASDAQ:TWST) will be posting its quarterly earnings results before the market opens on Monday, November 18th. Analysts expect Twist Bioscience to post earnings of ($0.73) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Twist Bioscience Trading Down 5.3 %

Shares of Twist Bioscience stock opened at $36.89 on Friday. The company has a 50 day moving average of $43.90 and a 200-day moving average of $46.02. The company has a market cap of $2.16 billion, a PE ratio of -9.66 and a beta of 1.78. Twist Bioscience has a 1-year low of $18.80 and a 1-year high of $60.90.

Wall Street Analysts Forecast Growth

TWST has been the topic of a number of research analyst reports. Leerink Partners raised their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. lifted their target price on Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research report on Monday, August 5th. Evercore ISI boosted their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Robert W. Baird raised their price target on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research note on Monday, August 5th. Finally, Barclays lowered their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.22.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, CAO Robert F. Werner sold 1,448 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $44.60, for a total value of $64,580.80. Following the sale, the chief accounting officer now owns 45,620 shares in the company, valued at approximately $2,034,652. The trade was a 3.08 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Dennis Cho sold 1,507 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $72,336.00. Following the transaction, the insider now owns 91,163 shares of the company’s stock, valued at $4,375,824. This trade represents a 1.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 98,118 shares of company stock worth $4,391,151 in the last quarter. 3.92% of the stock is owned by insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.